DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
FcRn Inhibitors for Autoimmune Disorders: A Promising Therapeutic Approach
Autoimmune disorders, a group of conditions where the immune system mistakenly attacks healthy cells, affect millions worldwide, often leading to debilitating symptoms and reduced quality of life. Traditional treatments for autoimmune disorders have primarily focused on suppressing the immune system, which can leave patients vulnerable to infections and other complications. However, recent advancements in medical research have opened up new avenues for targeted therapies, including the promising field of FcRn inhibitors. Understanding FcRn: Guardians of Immunoglobulins FcRn, or neonatal Fc receptor, plays a crucial role in the immune system by…
Insights into Cancer Cachexia Treatment: Unraveling the Mystery
Cancer cachexia, a debilitating condition characterized by severe weight loss and muscle wasting, complicates the battle against cancer. Approximately half of all patients with cancer experience cachexia. This rate of occurrence rises to as high as 86% in the last 1–2 weeks of life, with 45% of patients losing more than 10% of their original body weight over disease progression. Cancer cachexia impacts approximately 60% of the 1.4 million patients diagnosed with cancer in the United States each year. Additionally, the occurrence of cachexia varies across cancer types and ranges…
Xtant Medical’s SimipliGraft TM and SimpliMaxTM Launch; Perelel’s Fertility Support Products Expansion; Medtronic’s InceptivTM FDA Approval; GE Healthcare’s Vital Signs Monitor FDA 510(K) Clearance; Merck’s Pneumonia Vaccine Positive Results; Artivion’s Aortic Devices AATS Win
Xtant Medical Announced the Launch of SimipliGraft TM and SimpliMaxTM for Chronic and Acute Wounds On April 30, 2024, Xtant Medical Holdings, Inc., a global medical technology firm specializing in surgical remedies for spinal disorders, announced the complete commercial availability of two amniotic membrane allografts, known as SimpliGraft™ and SimpliMax™. SimpliGraft and SimpliMax are dehydrated, terminally irradiated sheets of amniotic membrane, available in single and dual layers. They are designed to act as a barrier, offering protective coverage against the surrounding environment when applied topically to both chronic and acute…
-Agonist.png "Toll-like Receptors Agonist")
